UK markets open in 3 hours 51 minutes

OncoCyte Corporation (OCX)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
2.7600-0.1700 (-5.80%)
At close: 04:00PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-63,809
-27,781
-72,902
-64,097
-29,932
Depreciation & amortisation
5,194
1,680
5,220
4,205
394
Deferred income taxes
97
-
0
-9,261
-1,254
Stock-based compensation
9,128
2,887
10,042
6,841
5,066
Change in working capital
-3,970
-3,971
-1,942
149
1,982
Accounts receivable
-958
109
-575
-1,229
-182
Accounts payable
666
-4,757
297
-1,348
848
Other working capital
-46,924
-23,606
-49,908
-38,188
-27,207
Other non-cash items
7,519
-4,241
-31,007
27,322
-3,908
Net cash provided by operating activities
-42,985
-23,325
-45,568
-35,941
-25,980
Cash flows from investing activities
Investments in property, plant and equipment
-3,939
-281
-4,340
-2,247
-1,227
Acquisitions, net
0
-
0
-11,714
-10,514
Sales/maturities of investments
-
367
0
-
-
Other investing activities
-
-
-
-
-7
Net cash used for investing activities
-3,939
-932
-4,340
-13,961
-11,748
Cash flows from financing activities
Debt repayment
-1,611
-117
-1,429
-1,534
-446
Common stock issued
32,844
13,848
32,843
77,987
20,805
Common stock repurchased
0
-1,118
0
-239
-14
Other financing activities
-482
-427
-483
-3,065
-132
Net cash used provided by (used for) financing activities
35,637
12,186
35,806
78,364
22,799
Net change in cash
-11,287
-12,071
-14,102
28,462
-14,929
Cash at beginning of period
45,040
23,203
37,305
8,843
23,772
Cash at end of period
33,753
11,132
23,203
37,305
8,843
Free cash flow
Operating cash flow
-42,985
-23,325
-45,568
-35,941
-25,980
Capital expenditure
-3,939
-281
-4,340
-2,247
-1,227
Free cash flow
-46,924
-23,606
-49,908
-38,188
-27,207